KUALA LUMPUR, Dec 19 (Bernama) -- Neuralstem Inc appointed Dr. Kenneth C. Carter as the company’s Executive Chairman of the Board, effective Jan 1, 2019. He will replace interim Chief Executive Officer, Jim Scully.
“Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies. His leadership will be invaluable to Neuralstem at a critical juncture in the company’s evolution,” said Chairman of the Board, William Oldaker.
Meanwhile, Dr. Carter looks forward to working with the team at Neuralstem to develop and execute on a strategic plan to deliver on promising therapies and maximise value for the shareholders.
Dr. Carter is a dynamic industry executive and scientific leader with deep experience in development-stage biotechnology companies. He is currently Chairman of the Board of Noble Life Sciences Inc, a pre-clinical contract research organisation, a statement said.
He has served numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics Inc, Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI).
Neuralstem is a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies.
-- BERNAMA
No comments:
Post a Comment